Supplementary
. Sequence alignment of CepI with related homologous acyl homoserine lactone synthase. Sequences have been selected based on availability of biochemical characterization and/or three-dimensional structures. Uniprot unique sequence identifiers are shown next to protein names. The alignment (generated with MUSCLE S1 ) highlights the conservation of predicted secondary structure features, the amino acid sequence and their solvent accessibility (acc, shown in a scale from white to blue to indicate highly and poorly solvent accessible, respectively) based on the CepI homology model. Critical residues for enzymatic activity are shown with a star symbol, either in red (highly conserved residues essential for catalysis), in blue (residues implicated in stabilization of the SAM substrate), or in green (positively charged residues implicated in binding and stabilization of the ACP substrate). Residues lining the putative hydrophobic cavity hosting the acyl moiety of AHL are shown with pink triangles. Supplementary Figure S5 . Molecular docking analysis of compound 8b onto CepI structure. Cartoon representation of the CepI homology model (shown in grey, orientation as in Supplementary Figure S4) showing the results of molecular docking using compound 8b. Optimized candidate ligand binding sites identified by molecular docking are shown with colored dots. Candidate sites proximate to structural elements critical for substrate recognition are shown in magenta, others in cyan.
Supplementary Figure S6 . Microphotographs of HeLa cells after 72h treatment with 8b and 6a. DMSO, cells treated with the highest amount of solvent. 10X and 20X indicate the magnification used. 

Supplementary Methods
Structural bioinformatics
Secondary structure prediction on CepI was performed through comparison of the results of multiple web servers including HHPRED S4 and PredictProtein S9 . The comparative evaluation of multiple structural prediction algorithms enabled unambiguous identification of the most prominent features of the proteins analyzed. The three-dimensional model of CepI was created using the homology modelling tools in HHPRED S4 and MODELLER S10 , and the alignment shown in Supplementary Fig. S1 . The model was further optimized by geometry idealization using PHENIX S11 . Final model quality was assessed using PROCHECK and PDBSUM S12 and the Qmean server S13 . Structural figures were generated using ESPript S14 and PyMol S15 .
Molecular Docking
Molecular docking of compound 8b was performed using the CepI homology model obtained as described above and the three-dimensional structure of the inhibitor generated by the PRODRG server S16 . Unconstrained ligand exploration trials for identification of candidate ligand binding sites were performed by repeated searches using the SWISSDOCK S17 and PELE S18 docking servers. Out of more than 100 parallel independent attempts of unconstrained ligand binding search, the best candidate sites were selected based on the lowest stabilization energy and used as templates for ligand binding refinement using PELE S19 . Each candidate binding contact was subject to 24 parallel runs of refinement (using 12 hours of minimization for each run). Final selection used to generate
Supplementary Figure S4 included ligand-bound conformations showing the lowest stabilization energies and ligand mobility.
General procedure for the synthesis diketopiperazine derivatives (Figure 8 in main text)
Step a). Suspension of 2',5'-Dihydroxyacetophenone (3.0 g, 19,7 mmol), benzyl chloride (4.5 ml, Step b). Suspension of 2',5'-dibenzyloxyacetophenone (3.0 g, 9.0 mmol) and selenium dioxide ( Step c). Suspension of [2,5-bis(benzyloxy)phenyl](oxo)acetic acid (2.5 g, 6.9 mmol) in 15 ml of carbon tetrachloride was treated by 2.5 ml of thionyl chloride and one drop of DMF. Reaction mixture was refluxed for 3 hours become clear solution and evaporated under vacuum. Oily residue was treated by toluene and evaporated under vacuum again. Colorless oil of [2,5-bis(benzyloxy)phenyl](oxo)acetyl chloride (quantitative yield) was immediately used in next step without any additional purification.
Step d). Solution of [2,5-bis(benzyloxy)phenyl](oxo)acetyl chloride (6.9 mmol) from previous step in 10 ml of dry DMF was treated by corresponding amino ester hydrochloride (7.0 mmol) and triethylamine (1.9 ml, 13.8 mmol). Reaction mixture was stored for 48 hours at room temperature on magnetic stirrer and evaporated under vacuum. Residue was treated by 10 ml of water, formed white precipitate was filtered off, washed by water and recrystallized from mixture ethanol/water.
Methyl [[[2,5-bis(benzyloxy) Step f). Solution of 3-[2,5-bis(benzyloxy)phenyl]-6-R-piperazine-2,5-dione (2 mmol) in 15 mlof DMF was treated by H 2 in presence of 0.1 g of 10% palladium on carbon for 4 hours at room temperature. Solution was filtered off, mother liquid was evaporated under vacuum and residue was treated by small volume of cold water. Formed white precipitate of 3-(2,5-dihydroxyphenyl)-6-Rpiperazine-2,5-dione was filtered off, washed by cold water and recrystallized from water. Step g). Suspension of 3-(2,5-dihydroxyphenyl)-6-R-piperazine-2,5-dione (2.0 mmol) in 1.5 ml acetic acid was treated by 0.1 ml of perchloric acid 70% solution in water, 0.2 ml of conc. sulfuric acid and 0.15 ml of fum. nitric acid. After 15 minutes reaction mixture become yellow solution and after 3 hours yellow precipitate formatted. Reaction mixture was dissolved by 3 ml of isopropyl alcohol, stored at -18 o C for 1 hour, filtered off and washed by 2 ml of cold isopropyl alcohol. Solid 3-(3,6-dioxocyclohexa-1,4-dien-1-yl)-6-R-piperazine-2,5-dione was immediately recrystallized from ethanol.
3-(2,5-Dihydroxyphenyl
3- (3,6-dioxocyclohexa-1,4-dien-1-yl) (3S)-3- Step h). Suspension of 3-(2,5-dihydroxyphenyl)piperazine-2,5-dione (0.7 g, 3.1 mmol) in 5 ml of acetic anhydride was refluxed for 6 hours. Reaction masse was evaporated and oily residue was recrystallized from ethanol. The yield of 2-(1,4-diacetyl-3,6-dioxopiperazin-2-yl)-1,4-phenylene diacetate 1.10 g (89%). 1, 
2-(
Preparation of recombinant Sfp and ACP proteins
ACP and Sfp were amplified from E. coli BL21(DE3) and B. subtilis PB1927 genomic DNA respectively, using ACPfor (5'-ATGAGCACTATCGAAGAACGC-3') and ACPrev (5'-TTACGCCTGGTGGCCGTTGAT-3') and Sfpfor (5'-ATGAAGATTTACGGAATTTAT-3') and 
MIC determination
The MICs (Minimal Inhibitory Concentrations) of the compounds reported in Supplementary Table   S1 were assessed against B. cenocepacia J2315 by using the 2-fold microdilution method in Ubottom 96-well microtiter plates.
About 10 5 CFU were used to inoculate each well of the microplate containing concentrations of compounds ranging from 1 to 128 µg/ml. Growth was determined by the resazurin method S22 after two days of incubation at 37 °C. 30 μl of a solution of resazurin sodium salt (Sigma Aldrich) at 0.01% in distilled water were added to each well, and the microtiters were incubated at 37 °C for about 4 h. The MIC was defined as the lowest concentration of the compound that prevented a change in color from blue to pink.
Synergistic experiments were performed using 20 µg/ml of 6a or 8b in combination with two-fold dilutions of ampicillin (1000-7.8 µg/ml), aztreonam (1000-7.8 µg/ml), ceftazidime (1000-7.8 µg/ml), chloramphenicol (32-0.25 µg/ml), ciprofloxacin (32-0.25 µg/ml), gentamicin (1000-7.8 µg/ml), kanamycin (1000-7.8 µg/ml), levofloxacin (32-0.25 µg/ml), meropenem (256-2 µg/ml), nalidixic acid (64-0.5 µg/ml), norfloxacin (256-2 µg/ml), sparfloxacin (64-0.5 µg/ml), streptomycin (1000-7.8 µg/ml), tetracycline (512-4 µg/ml), tobramycin (1000-7.8 µg/ml), trimethoprim (1000-7.8 µg/ml). The experiments were performed by the 2-fold microdilution method as described above.
